Strive (ASST) stock has drawn attention after a recent pullback, with the price down 8.6% in the past day and 17.3% over the past week. This has prompted closer scrutiny from investors.

Despite the sharp 1-day and 7-day share price declines, Strive’s 90-day share price return of 59.35% reflects earlier momentum that has recently faded, with the year-to-date share price return now down 14.76%.

If Strive’s swings have you thinking about diversification, this could be a good moment to scan other opportunities through the 39 healthcare AI stocks

With the stock down sharply in the short term but still showing a strong 90 day return and trading at a discount to a US$29.60 analyst price target, is this weakness a potential entry point, or is the market already baking in future growth?

Price-to-Book of 1.5x: Is it justified?

On a P/B basis, Strive trades at 1.5x, which sits below both its US Medical Equipment industry average of 2.2x and the peer group average of 1.8x.

P/B compares the market value of a stock to its book value, which is the net asset value on the balance sheet. For an asset-heavy business like Strive, this yardstick helps you see how much of a premium or discount investors are placing on its balance sheet relative to similar companies.

Here, the discount is clear, with the stock valued lower than both the wider industry and close peers. At the same time, Strive is currently unprofitable, reports a loss of $697.96m on revenue of $7.03m, and carries a negative return on equity, so the market could be weighing those factors heavily even as the stock is priced below asset levels compared to peers.

Compared with the US Medical Equipment average P/B of 2.2x and a peer average of 1.8x, Strive’s 1.5x level indicates the stock is priced at a steeper discount to book value than many competitors, suggesting the market is assigning a lower premium to its equity base than is typical across the group.

Result: Price-to-book of 1.5x (UNDERVALUED).

However, Strive’s recent share price pullback, sizeable loss of US$697.96m on US$7.03m revenue, and relatively small US$1.18b market cap could be associated with higher volatility.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment clearly mixed after the sharp pullback and earlier gains, it makes sense to review the numbers yourself and move quickly if you want conviction. To weigh up both sides of the story, start by reviewing Strive’s 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If you are weighing what to do with Strive now, this is a smart time to broaden your watchlist and compare it with other targeted opportunities.

• Seek potential mispricings by scanning 47 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their financial strength.
• Strengthen your income stream by reviewing 10 dividend fortresses that focus on higher yields paired with resilient business profiles.
• Prioritise resilience by checking 63 resilient stocks with low risk scores that aim to limit downside while still giving you meaningful equity exposure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.